 SAN DIEGO, June 30, 2021 PRNewswire -- NuVasive, Inc. NASDAQ: NUVA, the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that the Pulse platform received CE Mark approval for its latest design update and clinical evaluations are underway in multiple countries throughout Europe. The latest CE Mark approval and clinical evaluations are key commercialization milestones for the Pulse platform and further our plan for an expanded global launch later this summer, said Massimo Calafiore, executive vice president, Global Business Units at NuVasive. 